Explore original, structured summaries for research and education.
Research profile
SS-31(Elamipretide)
SS-31(Elamipretide) is indexed as a Aromatic-cationic tetrapeptide research entry. Its current evidence category is (Elamipretide), and published discussion commonly places it within Longevity, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- —
- Chain length
- —
- Type
- Aromatic-cationic tetrapeptide
- Reported half-life
- ~2 hours
Literature map
Research indications
Mitochondrial
- Enhanced ATP Productionmost effective
- Oxidative Stress Reductionmost effective
- Mitochondrial Disease Supporteffective
Cardiovascular
- Cardiac Protectioneffective
- Heart Failure Supporteffective
- Exercise Toleranceeffective
Anti-Aging
- Age-Related Muscle Functionmoderate
- Cognitive Protectionmoderate
- Cellular Rejuvenationmoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for SS-31(Elamipretide). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of SS-31(Elamipretide) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is SS-31(Elamipretide) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Randomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy (MMPOWER)Karaa, A., et al. · Neurology · 2018
- Novel Mitochondria-Targeting Peptide in Heart Failure Treatment (EMBRACE)Daubert, M.A., et al. · Circulation: Heart Failure · 2017
- Improving Mitochondrial Function with SS-31 Reverses Age-Related Redox Stress and Improves Exercise Tolerance in Aged MiceSiegel, M.P., et al. · Free Radical Biology and Medicine · 2019
- TAZPOWER: Phase 2/3 Randomized Clinical Trial of Elamipretide in Barth SyndromeThompson, W.R., et al. · Genetics in Medicine · 2021
- Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical TrialKaraa, A., et al. · JAMA Neurology · 2023
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic PotentialMachiraju, P., et al. · International Journal of Molecular Sciences · 2025